Ipsen SA (0MH6) RNS Announcements

Add to Alert list
Date Time Source Announcement
01 Dec 2025 06:00 AM
GNW
Ipsen mourns the passing of Henri Beaufour, a...
07 Nov 2025 01:42 PM
GNW
Ipsen to present two late-breaking sessions a...
22 Oct 2025 06:05 AM
GNW
Ipsen delivers strong sales in the first nine...
22 Oct 2025 06:00 AM
GNW
Ipsen to acquire ImCheck Therapeutics, expand...
22 Sep 2025 06:00 AM
GNW
Ipsen’s LANTIC Phase II in aesthetics deliver...
19 Sep 2025 12:59 PM
GNW
Bylvay® (odevixibat) approved in Japan for ra...
31 Jul 2025 06:00 AM
GNW
Ipsen delivers strong results in the first ha...
24 Jul 2025 06:41 PM
GNW
Cabometyx® approved in the EU for previously ...
23 Jul 2025 06:30 AM
GNW
Ipsen announces changes to its Executive Comm...
20 Jun 2025 11:19 AM
GNW
Ipsen receives positive CHMP opinion for Cabo...
31 May 2025 01:00 PM
GNW
Late-breaking analysis demonstrates character...
07 May 2025 07:00 AM
GNW
Late-breaking exploratory data highlights the...
06 May 2025 06:30 AM
GNW
Ipsen appoints Laura Réveillon as EVP, Strat...
24 Apr 2025 07:14 AM
GNW
Late-breaking elafibranor primary sclerosin...
16 Apr 2025 05:57 AM
GNW
Ipsen delivers strong sales in the first quar...
19 Mar 2025 06:00 AM
GNW
Ipsen announces issuance of €500 million inau...
12 Mar 2025 06:28 AM
GNW
Ipsen appoints Olivia Brown as Executive Vice...
13 Feb 2025 05:57 AM
GNW
Ipsen delivers solid results in 2024, driven ...
03 Dec 2024 06:00 AM
GNW
Ipsen and Biomunex announce exclusive global ...
18 Nov 2024 06:00 AM
GNW
Bylvay® (odevixibat) data shows sustained imp...
15 Nov 2024 04:00 PM
GNW
Iqirvo® (elafibranor) data shows efficacy and...
23 Oct 2024 06:00 AM
GNW
Ipsen delivers strong sales momentum in the f...
14 Oct 2024 05:00 PM
GNW
Ipsen receives its second Shingo Prize for op...
23 Sep 2024 12:13 PM
GNW
Ipsen’s Kayfanda® (odevixibat) approved in Eu...
20 Sep 2024 01:57 PM
GNW
Ipsen’s Iqirvo® (elafibranor) approved in the...
16 Sep 2024 01:45 PM
GNW
Final results from CABINET Phase III trial re...
15 Sep 2024 01:45 PM
GNW
Ipsen provides update on CONTACT-02 Phase III...
26 Jul 2024 11:46 AM
GNW
Ipsen receives CHMP positive opinions for Iqi...
25 Jul 2024 06:00 AM
GNW
Ipsen delivers strong results in the first ha...
25 Jul 2024 05:58 AM
GNW
Ipsen and Day One enter into exclusive ex-U.S...
11 Jul 2024 06:00 AM
GNW
Ipsen and Foreseen Biotechnology announce exc...
02 Jul 2024 06:00 AM
GNW
Ipsen expands collaboration and license agree...
10 Jun 2024 09:54 PM
GNW
Ipsen’s Iqirvo® receives U.S. FDA accelerated...
07 Jun 2024 06:00 AM
GNW
Ipsen and Marengo Therapeutics announce secon...
06 Jun 2024 01:30 PM
GNW
Ipsen appoints Josep Catllà as EVP, Chief Cor...
05 Jun 2024 07:00 AM
GNW
Ipsen presents long-term elafibranor efficacy...
02 May 2024 06:30 AM
GNW
Ipsen appoints Keira Driansky as EVP, Preside...
24 Apr 2024 06:00 AM
GNW
Ipsen delivers strong sales in the first quar...
22 Apr 2024 06:00 AM
GNW
Ipsen and Skyhawk Therapeutics announce RNA t...
02 Apr 2024 06:00 AM
GNW
Ipsen and Sutro Biopharma announce exclusive ...
13 Feb 2024 09:08 PM
GNW
Ipsen’s Onivyde® regimen, a potential new sta...
08 Feb 2024 05:58 AM
GNW
Building on solid FY 2023 results, Ipsen anti...
22 Jan 2024 10:00 PM
GNW
Latest Phase III trial data investigating Cab...
07 Dec 2023 06:00 AM
GNW
Ipsen confirms U.S. FDA grants priority revie...
07 Dec 2023 06:00 AM
GNW
Capital Markets Day 2023 - Ipsen outlines nex...
13 Nov 2023 09:30 PM
GNW
Results from Ipsen’s ELATIVE® pivotal Phase I...
26 Oct 2023 06:00 AM
GNW
Ipsen delivers solid sales growth in the firs...
23 Oct 2023 06:00 AM
GNW
Ipsen updates on E.U. Marketing Authorisation...
03 Oct 2023 05:00 PM
GNW
Ipsen updates on QM-1114 regulatory process
04 Sep 2023 06:00 AM
GNW
Ipsen nominates Pascal Touchon to its Board o...
UK 100

Latest directors dealings